MedPath

Xadcera Biopharmaceutical(Suzhou)Co.,Ltd.

πŸ‡¨πŸ‡³China
Ownership
-
Employees
-
Market Cap
-
Website

A Study of DM002 in Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Ovarian Neoplasms
Prostatic Neoplasms
Endometrial Neoplasms
Colorectal Neoplasms
Solid Carcinoma
Interventions
First Posted Date
2024-12-27
Last Posted Date
2025-04-17
Lead Sponsor
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Target Recruit Count
160
Registration Number
NCT06751329
Locations
πŸ‡ΊπŸ‡Έ

The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

πŸ‡¦πŸ‡Ί

Cancer Care Wollongong, Wollongong, New South Wales, Australia

A Study of DM001 in Patients With Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Carcinoma, Non-Small-Cell Lung
Breast Neoplasms
Solid Carcinoma
Interventions
First Posted Date
2024-06-26
Last Posted Date
2025-04-17
Lead Sponsor
Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Target Recruit Count
128
Registration Number
NCT06475937
Locations
πŸ‡ΊπŸ‡Έ

Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States

πŸ‡¦πŸ‡Ί

Icon Cancer Centre South Brisbane, South Brisbane, Queensland, Australia

πŸ‡¦πŸ‡Ί

Tasman Oncology Research, Southport, Queensland, Australia

and more 2 locations
Β© Copyright 2025. All Rights Reserved by MedPath